Traws Pharma, Inc. TRAW 深 沪
等待开盘 05-11 09:30:00 美东时间
2.19
+0.490
+28.82%
华盛通- 最 高2.3999
- 今 开2.06
- 成交量 8817.18万股
- 最 低 1.5514
- 昨 收 1.70
- 总市值 0
- 52周最高 3.25
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.995
- 委 比 -32.95%
- 总股本 --
- 历史最高 31.13
- 量 比 574.58
- 振 幅 49.91%
- 历史最低 0.103
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak
Traws Pharma shares jump after the company advanced hantavirus antiviral candidates amid global monitoring of a cruise ship outbreak.
05-08 22:41
Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid
Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 patients.
2025-12-17 22:26
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
Traws Pharma announces rigosertib shows 80% overall response rate in treating RDEB-associated cutaneous SCC, with 50% complete responses, marking a significant advancement in a rare and aggressive disease.
2025-06-03 11:00
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
Traws Pharma received FDA feedback on tivoxavir marboxil (TXM) for bird flu and seasonal flu, including the use of the Animal Rule. Positive preclinical data supports TXM's potential as a single-dose treatment, with plans for further development and stockpiling to address potential pandemics.
2025-05-27 12:00
Traws Pharma Announces Special Shareholders Meeting Results; Board Subsequently Approved A 1-For-25 Reverse Stock Split, Expected To Begin Trading On A Split-Adjusted Basis On September 23, 2024
Three proposals, including a reverse stock split, were submitted and approvedTraws Board subsequently approved a 1-for-25 reverse stock splitTraws' shares expected to begin trading on a split-adjusted basis on September
2024-09-18 04:06
Traws Pharma Q2 2024 GAAP EPS $(4.87), Sales $57.00K Down From $60.00K YoY
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(4.87) per share. The company reported $57.00 thousand in sales this quarter. This is a 5.00 percent decrease over sales of $60.00 thousand the same period last year.
2024-08-15 19:19
